Welsh et al.49 examined the glycemic effects of providing no-cost rtCGM to underinsured patients with T2D in a community setting.49 In this interim analysis, 32 individuals who were insulin-treated (n = 18) and noninsulin-treated (n = 14) with 9.9% baseline HbA1c were followed for 6 months. Here, INS is linked to type 2 diabetes mellitus.